NCT05279248 is a Phase 4 clinical trial of HPV+MMR（0d），HPV（6m） in Human Papilloma Virus Infection Type 16, sponsored by Zhejiang Provincial Center for Disease Control and Prevention.

Who is sponsoring NCT05279248?

NCT05279248 is sponsored by Zhejiang Provincial Center for Disease Control and Prevention.

What drugs are being tested in NCT05279248?

Interventions in NCT05279248: HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m）.

What condition does NCT05279248 study?

NCT05279248 studies Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles, Rubella, Mumps.

Is NCT05279248 still recruiting?

NCT05279248 is currently status unknown. Last updated 29 March 2022.

Last reviewed 2022-03-29 · How we verify

NCT05279248

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Status unknown Phase 4 Last updated 29 March 2022

What this trial tests

Phase 4 trial testing HPV+MMR（0d），HPV（6m） in Human Papilloma Virus Infection Type 16 in 300 participants. Status unknown.

Timeline

25 August 2021

Primary endpoint
31 December 2022

20 June 2023

Quick facts

Lead sponsor	Zhejiang Provincial Center for Disease Control and Prevention
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	25 August 2021
Primary completion	31 December 2022
Estimated completion	20 June 2023
Sites	2 locations across China

Drugs / interventions tested

HPV+MMR（0d），HPV（6m） — full drug profile →
HPV（0d），HPV（6m），MMR（7m） — full drug profile →
MMR（0d），HPV（1m），HPV（7m） — full drug profile →

Conditions studied

Human Papilloma Virus Infection Type 16 — all drugs for Human Papilloma Virus Infection Type 16 →
Human Papilloma Virus Infection Type 18 — all drugs for Human Papilloma Virus Infection Type 18 →
Measles — all drugs for Measles →
Rubella — all drugs for Rubella →

Sponsor

Zhejiang Provincial Center for Disease Control and Prevention — full company profile →

Who can join

Adults 13 to 14, female only, with Human Papilloma Virus Infection Type 16 or Human Papilloma Virus Infection Type 18. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429
Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.
Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, et al · · 2025 · cited 2× · PMID 41276263 · DOI 10.1002/14651858.cd015364.pub2

Verify or expand the search:

Other recruiting trials for Human Papilloma Virus Infection Type 16

Currently open trials in the same condition.

NCT07407569 — Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H · Phase 2 · recruiting
NCT05669911 — Development of a Self-collection Device for Cervical Cancer Screening · NA · active not recruiting

Other Zhejiang Provincial Center for Disease Control and Prevention trials

Trials by the same sponsor.

NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
NCT05373030 — Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses I · Phase 4 · unknown
NCT04817917 — Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Differen · Phase 4 · unknown
NCT04576910 — Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China · Phase 4 · completed
NCT04133584 — The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05279248 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial Center for Disease Control and Prevention
Last refreshed: 29 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing